ORGO - רווח למניה בשנים עשר החודשים האחרונים Organogenesis Holdings

Adherence to ESG standards through the modernization of biomaterial disposal strengthens the profile of Organogenesis Holdings (ORGO). This chart in the GURU.Markets terminal illustrates the TTM earnings per share, where the latest reading stands at -1.19. Financial stability is based on the sale of regenerative products (Apligraf), while the implementation of semi-autonomous packaging lines and bioreactors optimizes costs, supporting the stability of quotes for this indicator.
פילוחי נתונים אנליטיים מרוכזים עבור Organogenesis Corp (ORGO)

Annual net earnings per share measure real equity returns by dividing the final financial result by the total number of securities to eliminate the impact of issuance. By analyzing changes in the rolling annual EPS, an investor can see how Medicare rates and demand for bioengineered tissues translate into actual shareholder earnings, which determines the fundamental stability of Organogenesis Holdings (ORGO).